Field notes from the regulated-writing frontier.
Articles, essays, and technical writeups from the Asthra team and our advisor network. Written for medical writers, regulatory leads, and the people who hold them accountable.
Every Run, Every Quality Flag, in One Report — Asthra's End-of-Run QC
When the agent finishes drafting, Asthra runs a structured QC pass — cross-reference integrity, statistical-claim sourcing, citation density, gap detection — and ships a quality_report.json alongside the draft. Here is what it checks and why.
2026
Tables and Figures in the Chat — Agent-Driven Python You Can Audit
Adverse-event line listings, sales-exposure data, lab parameter shifts — the data behind a CSR or PSUR runs into thousands of rows. Asthra's data analysis agent handles the analysis inside the chat with deterministic Python, every step audit-logged. No manual filtering, no LLM-fabricated numbers.
2026
Walk-Away Drafting: How to Generate a CSR Overnight
Initiate the run, step away, and come back to the studio fully briefed. Asthra lands a first draft + bibliography + hyperlinks + QC report in 1–2 hours; the writer reviews and refines in the studio with the full agent history in view — nothing is lost between the run and your review.
2026
What's in a Regulatory-Grade Run Bundle
Every Asthra run ships four artifacts side by side — the .docx, traceability.json, quality_report.json, and run_manifest.json. Each one answers a specific question a regulator or auditor would ask, and together they make the deliverable portable, reproducible, and inspector-ready.
2026
Camizestrant and SERENA-6: Same Data, Different Regulatory Questions
EMA's CHMP recommended approval of AstraZeneca's camizestrant combination after SERENA-6 showed a 56% reduction in risk of progression or death. FDA's ODAC voted 6-3 against a favorable benefit-risk assessment for broadly the same proposed use, focusing on the pre-progression ESR1-triggered switch design. The FDA has now extended its review. The lesson for global submission teams is not that the data changed by region. It is that the regulatory question did.
2026
Lilly's Three Vaccine Deals: The Regulatory Writing Integration Problem Behind the $3.8B Bet
Eli Lilly announced agreements to acquire Curevo, LimmaTech Biologics, and Vaccine Company for up to approximately $3.83 billion. The strategic logic is infectious-disease prevention. The regulatory-writing problem is integration: three vaccine portfolios, three document histories, three sets of agency assumptions, and one acquirer-side writing organisation that has to make them coherent.
2026
Outlook's Fourth FDA Cycle: The Writing Playbook After Three CRLs and a Granted Appeal
Outlook Therapeutics expects to resubmit LYTENAVA/ONS-5010 for wet AMD in June 2026 after FDA granted its appeal and concluded that substantial evidence of effectiveness has been established. After three CRLs across manufacturing, inspectional, and efficacy issues, the fourth-cycle BLA is a case study in cross-cycle traceability and evidence reframing.
2026
BMS Signed Anthropic. The AI-in-Pharma Bet Is Real — and the Writing Room Is Where It Lands First.
BMS announced an Anthropic R&D partnership the same week a CRO report said AI keeps repeating the same trial-design mistakes. Both are true. The question isn't whether AI belongs in pharma — it's which layer of the workflow pays off first.
2026
One Molecule, Many Indications: Retatrutide and the Writing-Org Problem Sponsors Aren't Sized For
Retatrutide's Phase 3 obesity readout is the headline. The operating story is the program shape — one molecule running pivotal trials across obesity, T2D, OSA, MASH, cardiovascular outcomes and knee osteoarthritis, with the GLP class expanding into more indications behind it. That is not a hiring problem. It is a writing-architecture problem.
2026
From Prompt Engineering to Standards Engineering
The first wave of AI in regulatory writing was the chat box. We built a versioned skill registry instead — and it is becoming the system-of-record for how regulatory standards apply to a draft.
2026
Hyperlinks Belong in the Draft, Not the Publishing Phase
Cross-references in regulatory submissions usually get wired up weeks after the draft is locked. We moved that work into the draft itself — anchors at write time, hyperlinks before publishing.
2026
Literature Search Belongs Inside the Regulatory Draft
PubMed, ClinicalTrials.gov, and bioRxiv are now reachable from inside Asthra's chat — without the browser-tab detour that used to break a writer's flow and let evidence go stale.
2026
Atara, Pierre Fabre, and the Third-Shot Submission: Anatomy of a Post-Rejection Rewrite
FDA has indicated a path to reconsider Atara and Pierre Fabre's twice-rejected tabelecleucel BLA. In a third-shot package, the writing function becomes load-bearing: every claim, analysis, and cross-reference has to map back to the prior CRL.
2026
CDER Loses Its Chief: When the Drug Center's Top Reviewer Walks Mid-Cycle
Endpoints reports CDER chief Tracy Beth Høeg is expected to leave the FDA, days after Commissioner Makary's exit. The drug center is now the third top FDA seat in turnover inside two weeks. Sponsors with active CDER submissions need a reviewer-agnostic plan.
2026
Immgolis and Immgolis Intri: What the New Golimumab Biosimilars Tell Writers About Totality of Evidence
FDA approved Immgolis and Immgolis Intri as the first interchangeable biosimilars to Simponi and Simponi Aria in May 2026. For 351(k) writers, the useful lesson is not the approval count. It is the evidence hierarchy FDA highlighted: analytical similarity first, with PK and immunogenicity supporting the totality-of-evidence narrative.
2026
In Vivo Cell Engineering at ASGCT 2026: The IND-Enabling Writing Problem Behind the Science
ASGCT 2026 showed growing momentum around in vivo cell engineering, from in vivo CAR-T to gene writing and gene regulation platforms. The science is advancing quickly, but the IND-enabling writing challenge is still unresolved: how do sponsors build CMC and nonclinical narratives when the precedent base is thin and borrowed from adjacent modalities?
2026
The Zillow for Abandoned Gene Therapies: What an Acquirer Really Inherits
ASGCT and the Orphan Therapeutics Accelerator launched CGTxchange in May 2026 to help shelved cell and gene therapy programs find new sponsors. For acquirers, the regulatory file is not just diligence material. It is the operating manual for whether the asset can be restarted without losing agency context.
2026
CNPV Pilot at Seven Approvals: Bizengri and the Priority Voucher Pathway
The FDA's Commissioner's National Priority Voucher pilot just landed its seventh approval with Bizengri for NRG1-fusion cholangiocarcinoma. A June 4 public hearing will shape what comes next.
2026
FDA's Drug Repurposing RFI: Why This Is a Regulatory Writing Opportunity
The FDA opened a docket on May 13 asking for drug repurposing candidates — explicitly inviting AI/ML preclinical evidence. Comments are due through June 29. The window matters more than the form.
2026
From IPO to First Annual Report: The Disclosure Stack Newly Public Biotechs Miss
An IPO doubles a biotech's disclosure workload overnight. The regulatory writing function rarely gets re-resourced in time. Here is what gets missed and how to plan against it.
2026
Makary Out: What an Interim FDA Leadership Window Means for Your Active Submission
FDA Commissioner Marty Makary resigned May 12, 2026. Existing guidance stays operative; new guidance pauses. Every sponsor with a submission in flight should re-plan inside 90 days.
2026
Milestone Payments as a Writing-Pace Forcing Function
When a partnership milestone pays, the regulatory writing function inherits a calendar. The partnership announcement is the loud event. The document acceleration that follows is the quiet one.
2026
The $5B Impairment and the Documentation Lifecycle
When a commercial decision retroactively reshapes a product's value, the documentation stack does not auto-adjust. The CSL impairment this week is a case study in why regulatory writing needs to be in the room before the writedown.
2026
Biotech's New Company Model: Chinese Assets and the IND-Bridging Problem
Endpoints identified 18 US biotechs since 2025 launching with in-licensed Chinese clinical-stage assets. The startup model is new. The regulatory writing problem — bridging Chinese trial documentation into a US IND — is not.
2026
CNPV Pilot — Seven Approvals in Twelve Months. What the Voucher Program Tells Regulatory Writers.
Bizengri's NRG1-cholangiocarcinoma approval on May 8 marks the seventh FDA approval under the Commissioner's National Priority Voucher pilot. The pace is the signal. Here's what to read into it before the June 4 public hearing.
2026
Daiichi Sankyo's $950M ADC Write-Down: Decommissioning the Capex Bet
Daiichi recorded a ¥149.4B 'extraordinary loss' on May 8 after scrapping antibody-drug-conjugate manufacturing capacity. The decommissioning problem returns — this time at the capex level, with documentation implications that follow.
2026
Postapproval Pregnancy Safety: The Final Guidance and the PSUR Architecture Problem
FDA's May 8 final guidance on postapproval pregnancy safety studies adds new methodological expectations for pregnancy registries, RWD complements, and case-report studies. The labelling implications land squarely in the PSUR.
2026
The CBER Leadership Vacuum: What an Open Center Director Search Means for Cell and Gene Therapy Submissions
Endpoints reports the FDA has narrowed its search for a CBER leader without a name attached. Sponsors with active cell and gene therapy filings need a tactical read on what shifts during interim leadership periods.
2026
Decommissioning a Program's Documentation Stack: When the Sponsor Terminates
Pfizer ending its Trillium-related programs is the headline. The regulatory writing question is what happens to the documentation, the audit trail, and the institutional memory when a sponsor closes a program down — especially mid-stream.
2026
FDA Elsa 4.0 and HALO: When the Reviewer Has AI, Editing Alone Falls Behind
FDA just shipped Elsa 4.0 with custom agents, document generation, OCR, and secure search — and consolidated 40+ submission portals into HALO. The asymmetry between the reviewer's stack and the writer's stack just widened.
2026
FDA's One-Day Inspectional Assessments: Continuous Readiness Replaces Cycle Prep
The FDA's new one-day pilot ran 46 inspections in two months and is expanding through FY26. The era of preparing for inspection windows is ending — your documentation has to hold up cold.
2026
OND Custom 4.1: FDA's Internal Review Tooling Is Versioning Faster Than Most CSR Pipelines
The Office of New Drugs released version 4.1 of its custom review tooling on May 4, 2026. Two meaningful versions inside a year is the leading indicator. Here's how to read it.
2026
Orphan Drug Designation and the Six-Month CSR Calendar Reset
Orphan Drug Designation is celebrated as good news. For the regulatory writing function, it is a calendar event that compresses CSR, briefing book, and pre-BLA preparation into a much tighter window than most teams plan for.
2026
PDUFA VIII: Reading the FY27 Dear Colleague Letter as a Submission Volume Forecast
The FY27 PDUFA Dear Colleague Letter dropped on May 4. Most teams skim it for fee schedules. The strategic teams read it for what it implies about review capacity and submission throughput in 2027.
2026
Phase 2 Win + Capital Raise = Six Months of Documentation Crunch
A positive Phase 2 readout followed by a financing round looks like a celebration. For the regulatory writing function, it's the start of a 180-day timeline collision that most teams underestimate.
2026
Project Optimus and the ORR Bridge: When Confirmatory Readouts Have to Carry More Than the Primary
Post-Project Optimus, the FDA's tolerance for narrow ORR-based accelerated approvals has tightened. The CSR and BLA narrative for a confirmatory readout now has to do framing work the primary readout used to do alone.
2026
Beyond Frontier Models — Why Regulatory AI Needs a Purpose-Built Stack
Frontier LLMs and generic RAG aren't enough for regulatory writing. A purpose-built stack — document model, retrieval, planning, and verification — is what separates a demo from a draft a regulator will accept.
2026
Why Regulatory Writing Is Broken — And How Agentic AI Fixes It
Regulatory writing teams spend 60–70% of project time on mechanical document assembly while sponsors lose $1.4M per day of delay. Here's why generic AI tools fall short, and what an agentic, document-aware system actually changes.
2026
First PROTAC Approval Rewrites the Regulatory Playbook for Degraders
FDA's approval of vepdegestrant establishes the first regulatory precedent for PROTAC protein degraders, creating a framework that will shape development strategies across the emerging degrader landscape.
2026
FDA's First Non-Antipsychotic Dementia Agitation Approval Changes Treatment Paradigm
FDA approves Auvelity for Alzheimer's agitation, marking a breakthrough in dementia care. We analyze the regulatory pathway, novel endpoints, and what this means for CNS drug development.
2026
Kymera's KT-621 Fast Track: What Degrader Designations Signal for Respiratory Programs
FDA grants Fast Track to Kymera's IRAK4 degrader KT-621 for eosinophilic asthma. We analyze what this designation reveals about regulatory pathways for targeted protein degradation in respiratory disease.
2026
When Partnerships End, Documentation Inheritance Becomes a Regulatory Burden
Big pharma partnership terminations leave smaller biotechs holding jointly-authored documents that need sponsor re-issue. The regulatory writing burden of these terminations is rarely discussed but significant.
2025
Writer-Defined Provenance: Why Source Control Matters in AI-Assisted Regulatory Writing
How writer-defined provenance ensures that every piece of AI-generated regulatory content is traceable to its specific source document, section, table, or image.
2025
What Is Regulatory Writing Automation in Life Sciences?
A clear definition of regulatory writing automation: what it covers, which documents benefit most, and why the life sciences industry is adopting AI-assisted drafting now.
2025
CSR Timelines: From One Month to Less Than 10 Days
How AI-assisted drafting is compressing Clinical Study Report timelines from weeks of manual effort to days of focused writing, without compromising quality or traceability.
See Asthra on your documents.
Request a demo and we'll match Asthra's draft against your existing process — section by section.